Kidney Research and Clinical Practice

Korean Society of Nephrology (대한신장학회)
권호 표지
DOI QR코드

DOI QR Code

Common viral infections in kidney transplant recipients

  • Vanichanan, Jakapat (Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital) ;
  • Udomkarnjananun, Suwasin (Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital) ;
  • Avihingsanon, Yingyos (Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital) ;
  • Jutivorakool, Kamonwan (Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital)
  • Received : 2018.06.22
  • Accepted : 2018.10.07
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Infectious complications have been considered as a major cause of morbidity and mortality after kidney transplantation, especially in the Asian population. Therefore, prevention, early detection, and prompt treatment of such infections are crucial in kidney transplant recipients. Among all infectious complications, viruses are considered to be the most common agents because of their abundance, infectivity, and latency ability. Herpes simplex virus, varicella zoster virus, Epstein-Barr virus, cytomegalovirus, hepatitis B virus, BK polyomavirus, and adenovirus are well-known etiologic agents of viral infections in kidney transplant patients worldwide because of their wide range of distribution. As DNA viruses, they are able to reactivate after affected patients receive immunosuppressive agents. These DNA viruses can cause systemic diseases or allograft dysfunction, especially in the first six months after transplantation. Pretransplant evaluation and immunization as well as appropriate prophylaxis and preemptive approaches after transplant have been established in the guidelines and are used effectively to reduce the incidence of these viral infections. This review will describe the etiology, diagnosis, prevention, and treatment of viral infections that commonly affect kidney transplant recipients.

Keywords

References

  1. Ingsathit A, Avihingsanon Y, Rattanasiri S, et al. Different etiologies of graft loss and death in Asian kidney transplant recipients: a report from Thai Transplant Registry. Transplant Proc 42:4014-4016, 2010 https://doi.org/10.1016/j.transproceed.2010.09.061
  2. Tanabe K. Interinstitutional variation in the measurement of anti-A/B antibodies: the Japanese ABO-Incompatible Transplantation Committee survey. Transplantation 84(12 Suppl):S13- S16, 2007 https://doi.org/10.1097/01.tp.0000296018.82857.ef
  3. Fehr T, Cippa PE, Mueller NJ. Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy? Transpl Int 28:1351-1356, 2015 https://doi.org/10.1111/tri.12629
  4. Kotton CN, Kumar D, Caliendo AM; Transplantation Society International CMV Consensus Group, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-795, 2010 https://doi.org/10.1097/TP.0b013e3181cee42f
  5. Sumethkul V, Ingsathit A, Jirasiritham S. Ten-year followup of kidney transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 41:213-215, 2009 https://doi.org/10.1016/j.transproceed.2008.09.056
  6. Lee J, Cho JH, Lee JS, et al. Pretransplant hepatitis B viral infection increases risk of death after kidney transplantation: a multicenter cohort study in Korea. Medicine (Baltimore) 95:e3671, 2016 https://doi.org/10.1097/MD.0000000000003671
  7. Chancharoenthana W, Townamchai N, Pongpirul K, et al. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study. Am J Transplant 14:2814-2820, 2014 https://doi.org/10.1111/ajt.12921
  8. Locke JE, James NT, Mannon RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation 97:446- 450, 2014 https://doi.org/10.1097/01.TP.0000436905.54640.8c
  9. Boyarsky BJ, Durand CM, Palella FJ Jr, Segev DL. Challenges and clinical decision-making in HIV-to-HIV transplantation: insights from the HIV literature. Am J Transplant 15:2023-2030, 2015 https://doi.org/10.1111/ajt.13344
  10. Haywood AM. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J Virol 68:1-5, 1994
  11. Traylen CM, Patel HR, Fondaw W, et al. Virus reactivation: a panoramic view in human infections. Future Virol 6:451- 463, 2011 https://doi.org/10.2217/fvl.11.21
  12. Knipe DM, Howley PM, Griffin DE. Fundamental Virology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001
  13. Pang IK, Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol Rev 245: 209-226, 2012 https://doi.org/10.1111/j.1600-065X.2011.01073.x
  14. van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr Opin Immunol 20: 339-343, 2008 https://doi.org/10.1016/j.coi.2008.03.007
  15. Chappell JD, Dermody TS. 134 - Biology of viruses and viral diseases. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier Saunders, 1681-1693, 2015
  16. Randall RE, Griffin DE. Within host RNA virus persistence: mechanisms and consequences. Curr Opin Virol 23:35-42, 2017 https://doi.org/10.1016/j.coviro.2017.03.001
  17. Kane M, Golovkina T. Common threads in persistent viral infections. J Virol 84:4116-4123, 2010 https://doi.org/10.1128/JVI.01905-09
  18. Khanna KM, Lepisto AJ, Hendricks RL. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol 25:230-234, 2004 https://doi.org/10.1016/j.it.2004.02.010
  19. Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 82(2 Suppl):S9-S14, 2006
  20. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 9:2453-2458, 2009 https://doi.org/10.1111/j.1600-6143.2009.02824.x
  21. Roman A, Manito N, Campistol JM, et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev (Orlando) 28:84-91, 2014 https://doi.org/10.1016/j.trre.2014.01.001
  22. Carrillo-Infante C, Abbadessa G, Bagella L, Giordano A. Viral infections as a cause of cancer (review). Int J Oncol 30:1521-1528, 2007
  23. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 114:1209-1217, 2004 https://doi.org/10.1172/JCI200423395
  24. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 13 Suppl 4:93-106, 2013 https://doi.org/10.1111/ajt.12103
  25. Natori Y, Humar A, Husain S, et al. Recurrence of CMV Infection and the effect of prolonged antivirals in organ transplant recipients. Transplantation 101:1449-1454, 2017 https://doi.org/10.1097/TP.0000000000001338
  26. Nierenberg NE, Poutsiaka DD, Chow JK, et al. Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation. Liver Transpl 20:1497-1507, 2014
  27. Sarmiento E, Jaramillo M, Calahorra L, et al. Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: a multicenter prospective study. J Heart Lung Transplant 36:529-539, 2017 https://doi.org/10.1016/j.healun.2016.10.004
  28. Fernandez-Ruiz M, Silva JT, Lopez-Medrano F, et al. Posttransplant monitoring of NK cell counts as a simple approach to predict the occurrence of opportunistic infection in liver transplant recipients. Transpl Infect Dis 18: 552-565, 2016 https://doi.org/10.1111/tid.12564
  29. Sarmiento E, del Pozo N, Gallego A, et al. Decreased levels of serum complement C3 and natural killer cells add to the predictive value of total immunoglobulin G for severe infection in heart transplant recipients. Transpl Infect Dis 14:526-539, 2012 https://doi.org/10.1111/j.1399-3062.2012.00757.x
  30. Sarmiento E, Navarro J, Fernandez-Yanez J, Palomo J, Munoz P, Carbone J. Evaluation of an immunological score to assess the risk of severe infection in heart recipients. Transpl Infect Dis 16:802-812, 2014 https://doi.org/10.1111/tid.12284
  31. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 71:242-246, 2001 https://doi.org/10.1097/00007890-200101270-00013
  32. Kotton CN, Kumar D, Caliendo AM; The Transplantation Society International CMV Consensus Group, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102:900-931, 2018 https://doi.org/10.1097/TP.0000000000002191
  33. Chiasakul T, Townamchai N, Jutivorakool K, et al. Risk factors of cytomegalovirus disease in kidney transplant recipients: a single-center study in Thailand. Transplant Proc 47:2460-2464, 2015 https://doi.org/10.1016/j.transproceed.2015.08.011
  34. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 82(2 Suppl):S15-S17, 2006
  35. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician's update. Am J Kidney Dis 58:118-126, 2011 https://doi.org/10.1053/j.ajkd.2011.04.010
  36. Lopez-Oliva MO, Flores J, Madero R, et al. Cytomegalovirus infection after kidney transplantation and long-term graft loss. Nefrologia 37:515-525, 2017 https://doi.org/10.1016/j.nefro.2016.11.018
  37. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 12:848-855, 2001
  38. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10:1228-1237, 2010 https://doi.org/10.1111/j.1600-6143.2010.03074.x
  39. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6:2134-2143, 2006 https://doi.org/10.1111/j.1600-6143.2006.01413.x
  40. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 8:975-983, 2008 https://doi.org/10.1111/j.1600-6143.2007.02133.x
  41. Witzke O, Nitschke M, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegaloviruspositive renal allograft recipients: long-term results after 7 years of a randomized clinical trial. Transplantation 102: 876-882, 2018 https://doi.org/10.1097/TP.0000000000002024
  42. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8:69-77, 2008
  43. Asberg A, Humar A, Rollag H, et al. Lessons learned from a randomized study of oral valganciclovir versus parenteral ganciclovir treatment of cytomegalovirus disease in solid organ transplant recipients: the VICTOR trial. Clin Infect Dis 62:1154-1160, 2016 https://doi.org/10.1093/cid/ciw084
  44. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378: 549-562, 2018 https://doi.org/10.1056/NEJMra1702693
  45. Dierickx D, Tousseyn T, Sagaert X, et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 54:2433- 2440, 2013 https://doi.org/10.3109/10428194.2013.780655
  46. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 4: 928-936, 2004 https://doi.org/10.1111/j.1600-6143.2004.00451.x
  47. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 13 Suppl 3:41-54, 2013
  48. Morton M, Coupes B, Roberts SA, et al. Epstein-Barr virus infection in adult renal transplant recipients. Am J Transplant 14:1619-1629, 2014 https://doi.org/10.1111/ajt.12703
  49. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 86:206-209, 2011 https://doi.org/10.1002/ajh.21911
  50. Caillard S, Lamy FX, Quelen C; French Transplant Centers, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 12:682-693, 2012 https://doi.org/10.1111/j.1600-6143.2011.03896.x
  51. Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 13 Suppl 4:107-120, 2013 https://doi.org/10.1111/ajt.12104
  52. Hirsch HH, Randhawa P; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. Am J Transplant 13 Suppl 4:179-188, 2013
  53. Ambalathingal GR, Francis RS, Smyth MJ, Smith C, Khanna R. BK Polyomavirus: clinical aspects, immune regulation, and emerging therapies. Clin Microbiol Rev 30:503- 528, 2017 https://doi.org/10.1128/CMR.00074-16
  54. Yooprasert P, Rotjanapan P. BK virus-associated nephropathy: current situation in a resource-limited country. Transplant Proc 50:130-136, 2018 https://doi.org/10.1016/j.transproceed.2017.11.007
  55. Skulratanasak P, Mahamongkhonsawata J, Chayakulkeereeb M, Larpparisutha N, Premasathiana N, Vongwiwatana A. BK virus infection in Thai kidney transplant recipients: a single-center experience. Transplant Proc 50:1077-1079, 2018 https://doi.org/10.1016/j.transproceed.2018.02.047
  56. Fishman JA. Infection in organ transplantation. Am J Transplant 17:856-879, 2017 https://doi.org/10.1111/ajt.14208
  57. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 3:186-191, 2003 https://doi.org/10.1034/j.1600-6143.2003.30202.x
  58. Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant lowdose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5: 1997-2004, 2005 https://doi.org/10.1111/j.1600-6143.2005.00980.x
  59. Wu SW, Chang HR, Lian JD. The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 24:1034-1038, 2009
  60. Nesselhauf N, Strutt J, Bastani B. Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. J Nephropathol 5:34-37, 2016
  61. Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 20:962-969, 2007 https://doi.org/10.1111/j.1432-2277.2007.00523.x
  62. Zaman RA, Ettenger RB, Cheam H, Malekzadeh MH, Tsai EW. A novel treatment regimen for BK viremia. Transplantation 97:1166-1171, 2014 https://doi.org/10.1097/01.TP.0000441825.72639.4f
  63. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 89:1057-1070, 2010 https://doi.org/10.1097/TP.0b013e3181d0e15e
  64. Arroyo D, Chandran S, Vagefi PA, Wojciechowski D. Adjuvant ciprofloxacin for persistent BK polyomavirus infection in kidney transplant recipients. J Transplant 2014: 107459, 2014
  65. Umbro I, Anzivino E, Tinti F, et al. Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences. Virol J 10:274, 2013 https://doi.org/10.1186/1743-422X-10-274
  66. Lee BT, Gabardi S, Grafals M, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, doubleblinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol 9:583-589, 2014 https://doi.org/10.2215/CJN.04230413
  67. Khalil MAM, Khalil MAU, Tan J, Khan TFT. Fluoroquinolones and BK virus nephropathy: a myth or a reality. Indian J Nephrol 28:257-264, 2018
  68. Townamchai N, Thongboon A, Kittikowit W, Suankratay C, Praditpornsilpa K, Avihingsanon Y. Successful treatment of polyomavirus infection in kidney allograft recipients: case reports and literature review. Asian Biomed 3:151- 157, 2009
  69. Vu D, Shah T, Ansari J, Naraghi R, Min D. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc 47:394-398, 2015 https://doi.org/10.1016/j.transproceed.2015.01.012
  70. Kable K, Davies CD, O'Connell PJ, Chapman JR, Nankivell BJ. Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin. Trans plant Direct 3:e142, 2017 https://doi.org/10.1097/TXD.0000000000000641
  71. Luxemburger C, Dutta AK. Overlapping epidemiologies of Hepatitis A and typhoid fever: the needs of the traveler. J Travel Med 12 Suppl 1:S12-S21, 2005
  72. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: epidemiology and prevention in developing countries. World J Hepatol 4:68-73, 2012 https://doi.org/10.4254/wjh.v4.i3.68
  73. Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 28: 6653-6657, 2010 https://doi.org/10.1016/j.vaccine.2010.08.037
  74. Inoue K, Yoshiba M, Yotsuyanagi H, Otsuka T, Sekiyama K, Fujita R. Chronic hepatitis A with persistent viral replication. J Med Virol 50:322-324, 1996 https://doi.org/10.1002/(SICI)1096-9071(199612)50:4<322::AID-JMV7>3.0.CO;2-A
  75. Abolghasemi S, Sali S, Arabsaghari E, et al. Seroprevalence of hepatitis A in hemodialysis patient candidate for kidney transplant younger than forty years. Nov Biomed 2:49-53, 2017
  76. Mariya FA, de Mello Perez R, Silva AE, Pestana JO, Ferraz ML. Prevalence of previous hepatitis A virus infection in renal transplant patients with hepatitis C: evidence of persistent anti-hepatitis A virus immune response. Transplant Proc 36:1500-1501, 2004 https://doi.org/10.1016/j.transproceed.2004.05.034
  77. Levitsky J, Doucette K; AST Infectious Diseases Community of Practice. Viral hepatitis in solid organ transplantation. Am J Transplant 13 Suppl 4:147-168, 2013 https://doi.org/10.1111/ajt.12108
  78. Jeon HJ, Ro H, Jeong JC, et al. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transpl Infect Dis 16:511-515, 2014 https://doi.org/10.1111/tid.12217
  79. Stark K, Gunther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 180:2014-2017, 1999 https://doi.org/10.1086/315125
  80. Foster MA, Weil LM, Jin S, et al. Transmission of hepatitis A virus through combined liver-small intestine-pancreas transplantation. Emerg Infect Dis 23:590-596, 2017 https://doi.org/10.3201/eid2304.161532
  81. Gane E, Sallie R, Saleh M, Portmann B, Williams R. Clinical recurrence of hepatitis A following liver transplantation for acute liver failure. J Med Virol 45:35-39, 1995 https://doi.org/10.1002/jmv.1890450107
  82. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 57:442-450, 2012 https://doi.org/10.1016/j.jhep.2012.02.033
  83. Johnson DW, Dent H, Yao Q, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 24:1598-1603, 2009 https://doi.org/10.1093/ndt/gfn684
  84. Blanpain C, Knoop C, Delforge ML, et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation 66:883-886, 1998 https://doi.org/10.1097/00007890-199810150-00012
  85. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 94:151-156, 1988 https://doi.org/10.1016/0016-5085(88)90623-3
  86. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50:661-662, 2009 https://doi.org/10.1002/hep.23190
  87. Foster WQ, Murphy A, Vega DJ, Smith AL, Hott BJ, Book WM. Hepatitis B vaccination in heart transplant candidates. J Heart Lung Transplant 25:106-109, 2006 https://doi.org/10.1016/j.healun.2005.07.015
  88. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215-219; quiz e16-e17, 2015 https://doi.org/10.1053/j.gastro.2014.10.039
  89. Fytili P, Ciesek S, Manns MP, et al. Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. Transplantation 81:808-809, 2006 https://doi.org/10.1097/01.tp.0000198585.51562.57
  90. Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant 15:1162-1172, 2015 https://doi.org/10.1111/ajt.13187
  91. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol 19:17-25, 2013 https://doi.org/10.3350/cmh.2013.19.1.17
  92. Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: a review. World J Hepatol 7:885- 895, 2015 https://doi.org/10.4254/wjh.v7.i6.885
  93. Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol 11:172-182, 2015 https://doi.org/10.1038/nrneph.2015.5
  94. Morales JM, Marcen R, Andres A, et al. Renal transplantation in patients with hepatitis C virus antibody. A long national experience. NDT Plus 3(Suppl_2):ii41-ii46, 2010
  95. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol 2:563-575, 2007 https://doi.org/10.2215/CJN.02930806
  96. Pawlotsky JM. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis 34:22-29, 2014 https://doi.org/10.1055/s-0034-1371007
  97. Beinhardt S, Al Zoairy R, Ferenci P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int 29:999-1007, 2016 https://doi.org/10.1111/tri.12799
  98. Lin MV, Sise ME, Pavlakis M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One 11:e0158431, 2016 https://doi.org/10.1371/journal.pone.0158431
  99. Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother 49:674-687, 2015 https://doi.org/10.1177/1060028015576180
  100. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med 376:2394-2395, 2017 https://doi.org/10.1056/NEJMc1705221
  101. Ryu WS, Bayer M, Taylor J. Assembly of hepatitis delta virus particles. J Virol 66:2310-2315, 1992
  102. Adil B, Fatih O, Volkan I, et al. Hepatitis B virus and hepatitis D virus recurrence in patients undergoing liver transplantation for hepatitis B virus and hepatitis B virus plus hepatitis D virus. Transplant Proc 48:2119-2123, 2016 https://doi.org/10.1016/j.transproceed.2016.02.076
  103. Inagaki Y, Oshiro Y, Tanaka T, et al. A nationwide survey of hepatitis E virus infection and chronic hepatitis E in liver transplant recipients in Japan. EBioMedicine 2:1607-1612, 2015 https://doi.org/10.1016/j.ebiom.2015.09.030
  104. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 15:1225-1228, 2009 https://doi.org/10.1002/lt.21819
  105. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358:811-817, 2008 https://doi.org/10.1056/NEJMoa0706992
  106. Koning L, Pas SD, de Man RA, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. J Heart Lung Transplant 32:78-85, 2013 https://doi.org/10.1016/j.healun.2012.10.008
  107. Kamar N, Weclawiak H, Guilbeau-Frugier C, et al. Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation 93:617-623, 2012
  108. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 16:74-82, 2010 https://doi.org/10.1002/lt.21958
  109. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140:1481-1489, 2011 https://doi.org/10.1053/j.gastro.2011.02.050
  110. Kamar N, Rostaing L, Abravanel F, et al. Pegylated interferon- alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 50:e30-e33, 2010 https://doi.org/10.1086/650488
  111. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 370:1111-1120, 2014 https://doi.org/10.1056/NEJMoa1215246
  112. Locke JE, Gustafson S, Mehta S, et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg 265:604-608, 2017 https://doi.org/10.1097/SLA.0000000000001761
  113. Roland ME, Barin B, Huprikar S, et al; HIVTR Study Team. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS 30:435-444, 2016
  114. Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol 5:582-589, 2009
  115. Locke JE, Mehta S, Reed RD, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol 26:2222-2229, 2015 https://doi.org/10.1681/ASN.2014070726
  116. Malat GE, Ranganna KM, Sikalas N, Liu L, Jindal RM, Doyle A. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial. Transplantation 94:1020-1024, 2012
  117. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 363:2004-2014, 2010 https://doi.org/10.1056/NEJMoa1001197
  118. Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 170:4077-4086, 2003 https://doi.org/10.4049/jimmunol.170.8.4077
  119. Tanchot C, Rosado MM, Agenes F, Freitas AA, Rocha B. Lymphocyte homeostasis. Semin Immunol 9:331-337, 1997 https://doi.org/10.1006/smim.1997.0090
  120. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP. Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 8:1641-1652, 1992 https://doi.org/10.1089/aid.1992.8.1641
  121. van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MP, van Zuilen AD. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. Transplantation 95:397-402, 2013 https://doi.org/10.1097/TP.0b013e3182734651
  122. Sawinski D, Shelton BA, Mehta S, et al. Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant 17: 3114-3122, 2017 https://doi.org/10.1111/ajt.14419
  123. Miro JM, Aguero F, Duclos-Vallee JC, et al; ESCMID Study Group of Infection in Compromised Hosts. Infections in solid organ transplant HIV-infected patients. Clin Microbiol Infect 20 Suppl 7:119-130, 2014
  124. Kucirka LM, Durand CM, Bae S, et al. Induction immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus. Am J Transplant 16:2368-2376, 2016 https://doi.org/10.1111/ajt.13840
  125. Lopez C, Simmons RL, Mauer SM, Najarian JS, Good RA, Gentry S. Association of renal allograft rejection with virus infections. Am J Med 56:280-289, 1974 https://doi.org/10.1016/0002-9343(74)90609-3
  126. Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant 15:3024-3040, 2015 https://doi.org/10.1111/ajt.13486
  127. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis 2:539-549, 2002 https://doi.org/10.1016/S1473-3099(02)00370-5
  128. Borchers AT, Perez R, Kaysen G, Ansari AA, Gershwin ME. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 7:75-82, 1999 https://doi.org/10.1016/S0966-3274(99)80023-9
  129. Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol 7:2058-2070, 2012 https://doi.org/10.2215/CJN.04410512
  130. Storsley L, Gibson IW. Adenovirus interstitial nephritis and rejection in an allograft. J Am Soc Nephrol 22:1423-1427, 2011 https://doi.org/10.1681/ASN.2010090941
  131. Cippa PE, Schiesser M, Ekberg H, et al. Risk stratification for rejection and infection after kidney transplantation. Clin J Am Soc Nephrol 10:2213-2220, 2015 https://doi.org/10.2215/CJN.01790215
  132. Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12:1321-1336, 2017 https://doi.org/10.2215/CJN.13221216
  133. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15:266-282, 2014 https://doi.org/10.1016/j.chom.2014.02.011
  134. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 15:1582-1588, 2004 https://doi.org/10.1097/01.ASN.0000126194.77004.9B
  135. Hickman LA, Sawinski D, Guzzo T, Locke JE. Urologic malignancies in kidney transplantation. Am J Transplant 18: 13-22, 2018
  136. Alexiev BA, Randhawa P, Vazquez Martul E, et al. BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. Hum Pathol 44:908-917, 2013 https://doi.org/10.1016/j.humpath.2012.09.019
  137. Mittal A, Colegio OR. Skin cancers in organ transplant recipients. Am J Transplant 17:2509-2530, 2017 https://doi.org/10.1111/ajt.14382
  138. Dantal J, Campone M. Daunting but worthy goal: reducing the de novo cancer incidence after transplantation. Transplantation 100:2569-2583, 2016 https://doi.org/10.1097/TP.0000000000001428
  139. Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2:604-610, 2007 https://doi.org/10.2215/CJN.03931106
  140. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317-1323, 2005 https://doi.org/10.1056/NEJMoa042831
  141. de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation 101:45-55, 2017

Cited by

  1. Simultaneous detection of opportunistic viral infections among renal transplant patients from Sina Hospital, Tehran vol.14, pp.6, 2018, https://doi.org/10.2217/fvl-2018-0192
  2. Ginseng increases Klotho expression by FoxO3-mediated manganese superoxide dismutase in a mouse model of tacrolimus-induced renal injury vol.11, pp.15, 2018, https://doi.org/10.18632/aging.102137
  3. Urobiome: In Sickness and in Health vol.7, pp.11, 2018, https://doi.org/10.3390/microorganisms7110548
  4. A retrospective study of the relationship between postoperative urine output and one year transplanted kidney function vol.19, pp.1, 2018, https://doi.org/10.1186/s12871-019-0904-6
  5. Evaluation of cell-mediated immune response by QuantiFERON Monitor Assay in kidney transplant recipients presenting with infective complications vol.99, pp.27, 2018, https://doi.org/10.1097/md.0000000000021010
  6. Recent Advances and Clinical Outcomes of Kidney Transplantation vol.9, pp.4, 2020, https://doi.org/10.3390/jcm9041193
  7. The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with Pneumocystis jirovecii pneumonia vol.64, pp.5, 2018, https://doi.org/10.1111/1348-0421.12778
  8. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients vol.35, pp.24, 2018, https://doi.org/10.3346/jkms.2020.35.e185
  9. Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study vol.55, pp.8, 2018, https://doi.org/10.1080/00365521.2020.1790649
  10. Two distinct cases with COVID‐19 in kidney transplant recipients vol.20, pp.8, 2020, https://doi.org/10.1111/ajt.15947
  11. Cervical cancer screening abnormalities in immunosuppressed renal transplant women: case-control study in Southern Brazil vol.302, pp.3, 2018, https://doi.org/10.1007/s00404-020-05621-3
  12. ORIENTAÇÕES RELACIONADAS AO AUTOCUIDADO EM PACIENTES TRANSPLANTADOS: UMA REVISÃO NARRATIVA vol.32, pp.3, 2018, https://doi.org/10.14450/2318-9312.v32.e3.a2020.pp179-191
  13. ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial vol.20, pp.1, 2018, https://doi.org/10.1186/s12911-020-01146-6
  14. Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials vol.35, pp.1, 2018, https://doi.org/10.1016/j.trre.2020.100587
  15. Cytomegalovirus tubulo‐glomerulitis and intratubular granuloma: Key histopathological findings in allograft cytomegalovirus infection vol.26, pp.4, 2021, https://doi.org/10.1111/nep.13810
  16. Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real‐world evidence vol.23, pp.2, 2018, https://doi.org/10.1111/tid.13483
  17. Performance evaluation of the Roche cobas 6800 system for quantifying cytomegalovirus DNA in plasma and urine samples vol.138, pp.None, 2018, https://doi.org/10.1016/j.jcv.2021.104816
  18. Recovery of kidney function after AKI because of COVID‐19 in kidney transplant recipients vol.34, pp.6, 2021, https://doi.org/10.1111/tri.13886
  19. A systematic review and meta-analysis of enzyme-linked immunosorbent spot (ELISPOT) assay for BK polyomavirus immune response monitoring after kidney transplantation vol.140, pp.None, 2021, https://doi.org/10.1016/j.jcv.2021.104848
  20. A Current Review of the Etiology, Clinical Features, and Diagnosis of Urinary Tract Infection in Renal Transplant Patients vol.11, pp.8, 2018, https://doi.org/10.3390/diagnostics11081456